Wells Fargo’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.28K Buy
+100
New +$6.96K ﹤0.01% 6066
2025
Q3
Sell
-300
Closed -$26.2K 7159
2025
Q2
$26.2K Buy
+300
New +$23.5K ﹤0.01% 5714
2019
Q4
Sell
-220,000
Closed -$99K 6412
2019
Q3
$99K Sell
220,000
-128,000
-37% -$4.97M ﹤0.01% 5322
2019
Q2
$211K Buy
+348,000
New +$10.9M ﹤0.01% 4945

Other funds holding DXCM

Wells Fargo's DXCM Position: Q1 2026 in Review

Wells Fargo increased its DexCom (DXCM) stake by 4.2% in Q1 2026, buying an estimated $2.38M and bringing the position to 845,998 shares worth $53.1M. The position accounts for 0.01% of the portfolio, ranked #934.

Wells Fargo first reported a position in DXCM in Q2 2013 and has held it in 52 quarters since. The position peaked at $546M in Q3 2021. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

  • Wells Fargo held 845,998 shares of DexCom worth $53.1M as of Q1 2026.
  • Wells Fargo bought 34,127 DexCom shares in Q1 2026, an estimated $2.38M.
  • DexCom made up 0.01% of Wells Fargo's portfolio in Q1 2026, its #934 holding.
  • Wells Fargo first reported a position in DexCom in Q2 2013 and has held it in 52 quarters since.
  • Wells Fargo's DexCom position peaked at $546M in Q3 2021.
  • 956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.